These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 36985481)
1. Design, Synthesis and Biological Evaluation of Quinoline-8-Sulfonamides as Inhibitors of the Tumor Cell-Specific M2 Isoform of Pyruvate Kinase: Preliminary Study. Marciniec K; Rzepka Z; Chrobak E; Boryczka S; Latocha M; Wrześniok D; Beberok A Molecules; 2023 Mar; 28(6):. PubMed ID: 36985481 [TBL] [Abstract][Full Text] [Related]
2. Synthesis, Docking, and Machine Learning Studies of Some Novel Quinolinesulfonamides-Triazole Hybrids with Anticancer Activity. Marciniec K; Nowakowska J; Chrobak E; Bębenek E; Latocha M Molecules; 2024 Jul; 29(13):. PubMed ID: 38999109 [TBL] [Abstract][Full Text] [Related]
3. New pyridin-3-ylmethyl carbamodithioic esters activate pyruvate kinase M2 and potential anticancer lead compounds. Zhang Y; Liu B; Wu X; Li R; Ning X; Liu Y; Liu Z; Ge Z; Li R; Yin Y Bioorg Med Chem; 2015 Aug; 23(15):4815-4823. PubMed ID: 26081759 [TBL] [Abstract][Full Text] [Related]
4. Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC). Li RZ; Fan XX; Shi DF; Zhu GY; Wang YW; Luo LX; Pan HD; Yao XJ; Leung EL; Liu L Chem Biol Drug Des; 2018 Nov; 92(5):1851-1858. PubMed ID: 29931766 [TBL] [Abstract][Full Text] [Related]
5. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase. Ning X; Qi H; Li R; Li Y; Jin Y; McNutt MA; Liu J; Yin Y Eur J Med Chem; 2017 Sep; 138():343-352. PubMed ID: 28688274 [TBL] [Abstract][Full Text] [Related]
6. Structure-Guided Approach to Discover Tuberosin as a Potent Activator of Pyruvate Kinase M2, Targeting Cancer Therapy. Adnan M; Shamsi A; Elasbali AM; Siddiqui AJ; Patel M; Alshammari N; Alharethi SH; Alhassan HH; Bardakci F; Hassan MI Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361954 [TBL] [Abstract][Full Text] [Related]
7. 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Walsh MJ; Brimacombe KR; Veith H; Bougie JM; Daniel T; Leister W; Cantley LC; Israelsen WJ; Vander Heiden MG; Shen M; Auld DS; Thomas CJ; Boxer MB Bioorg Med Chem Lett; 2011 Nov; 21(21):6322-7. PubMed ID: 21958545 [TBL] [Abstract][Full Text] [Related]
8. Knockdown of the M2 Isoform of Pyruvate Kinase (PKM2) with shRNA Enhances the Effect of Docetaxel in Human NSCLC Cell Lines In Vitro. Yuan S; Qiao T; Zhuang X; Chen W; Xing N; Zhang Q Yonsei Med J; 2016 Nov; 57(6):1312-23. PubMed ID: 27593857 [TBL] [Abstract][Full Text] [Related]
9. Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. Mukherjee J; Phillips JJ; Zheng S; Wiencke J; Ronen SM; Pieper RO PLoS One; 2013; 8(2):e57610. PubMed ID: 23451252 [TBL] [Abstract][Full Text] [Related]
10. Anti-tumor effects of novel alkannin derivatives with potent selectivity on comprehensive analysis. Dai ZQ; Gao F; Zhang ZJ; Lu MJ; Luo YJ; Zhang T; Shang BX; Gu YH; Zeng Q; Gao S; Guo ZQ; Xu B; Lei HM Phytomedicine; 2023 Aug; 117():154912. PubMed ID: 37295023 [TBL] [Abstract][Full Text] [Related]
11. Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator. Matsui Y; Yasumatsu I; Asahi T; Kitamura T; Kanai K; Ubukata O; Hayasaka H; Takaishi S; Hanzawa H; Katakura S Bioorg Med Chem; 2017 Jul; 25(13):3540-3546. PubMed ID: 28511909 [TBL] [Abstract][Full Text] [Related]
12. Biochemical and structural insights into how amino acids regulate pyruvate kinase muscle isoform 2. Nandi S; Dey M J Biol Chem; 2020 Apr; 295(16):5390-5403. PubMed ID: 32144209 [TBL] [Abstract][Full Text] [Related]
13. Pyruvate kinase: Function, regulation and role in cancer. Israelsen WJ; Vander Heiden MG Semin Cell Dev Biol; 2015 Jul; 43():43-51. PubMed ID: 26277545 [TBL] [Abstract][Full Text] [Related]
14. Combining structure-based pharmacophore modeling, virtual screening, and in silico ADMET analysis to discover novel tetrahydro-quinoline based pyruvate kinase isozyme M2 activators with antitumor activity. Chen C; Wang T; Wu F; Huang W; He G; Ouyang L; Xiang M; Peng C; Jiang Q Drug Des Devel Ther; 2014; 8():1195-210. PubMed ID: 25214764 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform. Ning X; Qi H; Li R; Jin Y; McNutt MA; Yin Y J Enzyme Inhib Med Chem; 2018 Dec; 33(1):126-129. PubMed ID: 29185365 [TBL] [Abstract][Full Text] [Related]
16. A novel pyruvate kinase M2 activator compound that suppresses lung cancer cell viability under hypoxia. Kim DJ; Park YS; Kim ND; Min SH; You YM; Jung Y; Koo H; Noh H; Kim JA; Park KC; Yeom YI Mol Cells; 2015 Apr; 38(4):373-9. PubMed ID: 25813626 [TBL] [Abstract][Full Text] [Related]
17. Pyruvate kinase M knockdown-induced signaling via AMP-activated protein kinase promotes mitochondrial biogenesis, autophagy, and cancer cell survival. Prakasam G; Singh RK; Iqbal MA; Saini SK; Tiku AB; Bamezai RNK J Biol Chem; 2017 Sep; 292(37):15561-15576. PubMed ID: 28778925 [TBL] [Abstract][Full Text] [Related]
18. Roadmap to Pyruvate Kinase M2 Modulation - A Computational Chronicle. Kapoor S; Chatterjee DR; Chowdhury MG; Das R; Shard A Curr Drug Targets; 2023; 24(6):464-483. PubMed ID: 36998144 [TBL] [Abstract][Full Text] [Related]
19. Discovery and structure-activity relationship of novel 4-hydroxy-thiazolidine-2-thione derivatives as tumor cell specific pyruvate kinase M2 activators. Li R; Ning X; Zhou S; Lin Z; Wu X; Chen H; Bai X; Wang X; Ge Z; Li R; Yin Y Eur J Med Chem; 2018 Jan; 143():48-65. PubMed ID: 29172082 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Boxer MB; Jiang JK; Vander Heiden MG; Shen M; Skoumbourdis AP; Southall N; Veith H; Leister W; Austin CP; Park HW; Inglese J; Cantley LC; Auld DS; Thomas CJ J Med Chem; 2010 Feb; 53(3):1048-55. PubMed ID: 20017496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]